ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $446,893 | -12.2% | 4,168 | 0.0% | 0.30% | -13.4% |
| Q4 2022 | $509,038 | +18.4% | 4,168 | 0.0% | 0.35% | +28.1% |
| Q3 2022 | $430,000 | +11.1% | 4,168 | 0.0% | 0.27% | +3.0% |
| Q2 2022 | $387,000 | -20.9% | 4,168 | 0.0% | 0.27% | +14.7% |
| Q1 2022 | $489,000 | -71.2% | 4,168 | -66.9% | 0.23% | -53.8% |
| Q4 2021 | $1,695,000 | – | 12,600 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |